Literature DB >> 2959472

Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.

O G Berlin1, L S Young, S A Floyd-Reising, D A Bruckner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2959472     DOI： 10.1007/bf02013117

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Preparation of tuberculosis susceptibility testing mediums by means of impregnated disks.

Authors:  L G Wayne; I Krasnow
Journal:  Am J Clin Pathol       Date:  1966-06       Impact factor: 2.493

2.  Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency.

Authors:  P Zakowski; S Fligiel; G W Berlin; L Johnson
Journal:  JAMA       Date:  1982-12-10       Impact factor: 56.272

3.  Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

Authors:  D Y Rosenzweig
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

4.  Mycobacterium avium: a pathogen of patients with acquired immunodeficiency syndrome.

Authors:  O G Berlin; P Zakowski; D A Bruckner; M N Clancy; B L Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

5.  Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida.

Authors:  A E Pitchenik; C Cole; B W Russell; M A Fischl; T J Spira; D E Snider
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391
  5 in total
  10 in total

1.  In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

Authors:  J Biehle; S J Cavalieri
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 4.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

5.  Clarithromycin therapy of experimental Treponema pallidum infections in hamsters.

Authors:  J Alder; K Jarvis; M Mitten; N L Shipkowitz; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

Authors:  F de Lalla; R Maserati; P Scarpellini; P Marone; R Nicolin; F Caccamo; R Rigoli
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 7.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

8.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

10.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.

Authors:  B A Brown; R J Wallace; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.